Posaconazole prophylaxis in hematologic cancer.
Kontoyiannis
Dimitrios P
DP
Lewis
Russell E
RE
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001230:Aspergillus / Q000187:drug effects / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D025141:Drug Resistance, Fungal / Q000235:genetics; D006801:Humans; D052016:Mucositis; D009181:Mycoses / Q000517:prevention & control*; D009894:Opportunistic Infections / Q000517:prevention & control*; D010088:Oxidoreductases / Q000235:genetics; D017354:Point Mutation; D011743:Pyrimidines / Q000627:therapeutic use*; D058886:Sterol 14-Demethylase; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; C548418:CYP51A1 protein, human; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D003577:Cytochrome P-450 Enzyme System; D010088:Oxidoreductases; D058886:Sterol 14-Demethylase; D065819:Voriconazole